Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Endocrine Therapy in Stage 2-3 Invasive Lobular Carcinoma
NCT07483307Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
A Phase 2 trial of anastrozole, letrozole, exemestane, tamoxifen in Invasive Lobular Carcinoma (ILC), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2026; status: recruiting.
02
Drugs
anastrozoleletrozoleexemestanetamoxifen
03
Conditions
Invasive Lobular Carcinoma (ILC)
Beyond the preview
Go deeper on NCT07483307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483307.